Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

March 10, 2022

Lead Product Candidate, IMM-1-104, displays broad activity against a wide range of animal tumor models driven by MAPK pathway activating mutations including KRAS-G12D, KRAS-G12S, KRAS-G12C, NRAS-Q61R, and BRAF-V600E; IND filing is expected in Q3 2022

IMM-6-415, designed to sensitize otherwise-resistant tumors to select immunotherapies, moves into IND-enabling studies

Cash, cash equivalents and marketable securities of $150.2M is expected to provide cash runway into Q3 2024

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided recent business updates.

“2021 was a transformational year for Immuneering,” stated Ben Zeskind, Ph.D., MBA, co-founder and Chief Executive Officer of Immuneering. “Our lead program IMM-1-104 advanced steadily through IND-enabling studies, amassing a preclinical data package showing regressions or tumor stasis in animal models of tumors driven by five different MAPK pathway activating mutations, with good tolerability. Additionally, our MEK-io candidate, IMM-6-415, progressed into IND-enabling studies, with the goal of meaningfully increasing the number of cancer patients who respond well to select immunotherapies. Our earlier stage pipelines, in oncology and neurodegeneration, have made excellent progress, and we continued to expand and enhance our proprietary, translational bioinformatics platform. 

We also became a public company in 2021, and our upsized initial public offering provided the capital needed to bring our lead program, IMM-1-104, into the clinic, move the rest of our pipeline toward IND submissions and provided a cash runway into the third quarter of 2024. I am proud to work with the exceptional team that brought us to this point, and honored by all the great new hires and board members who joined us over the past year. The entire company has hit the ground running in 2022, moving at full speed toward our anticipated filing of the IND application for IMM-1-104 in the third quarter of this year, and enrollment of the first patient in the fourth quarter. I have never been more excited about the progress towards our longstanding goal of creating better medicines for cancer patients.”

Corporate Highlights

  • Preclinical Data Positions IMM-1-104 as Potential Treatment in NRAS Mutant Melanoma: In January 2022, Immuneering presented preclinical data in a presentation titled, “Head-to-Head Comparison of the Dual-MEK Inhibitor IMM-1-104 Versus Binimetinib in NRAS Mutant Melanoma Models,” by Vice President and Head of Discovery Peter King, PhD. IMM-1-104 was observed to exhibit superior tumor growth inhibition relative to binimetinib in the SK-MEL-2 melanoma xenograft mouse model displaying the NRAS-Q61R mutation. The video presentation is available at: Immuneering also hosted a key expert event with Dr. Anna Pavlick, a leading melanoma expert and current Professor of Medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine, to discuss the NRAS mutant melanoma treatment landscape. A replay of this event is available at:
  • IMM-1-104 Preclinical Data Presented at EORTC 2021: In October 2021, Immuneering presented data from three posters showcasing IMM-1-104 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The study authors concluded that IMM-1-104 displayed broad activity across a wide range of animal tumor models with diverse RAS and RAF mutations including KRAS-G12C, KRAS-G12D, KRAS-G12S, NRAS-Q61R, and BRAF-V600E. In addition, IMM-1-104 prompted tumor regressions similar to sotorasib in a KRAS-G12C mutant pancreatic xenograft model (MIA PaCa-2) and led to deeper durable tumor regressions in combination with sotorasib when compared to either drug alone. Transcriptomic data that was presented confirmed IMM-1-104’s deep cyclic inhibition by demonstrating strong MAPK pathway inhibition at two hours post-treatment, with a near complete release at 12 hours post-treatment. Additionally, through its short half-life, IMM-1-104 was observed to have an encouraging tolerability profile across animal models that, together with its broader applicability to RAS mutant tumors, may provide differentiation from FDA-approved MEK inhibitors. Immuneering also hosted a key external expert event to discuss this data with two leading KRAS mutation Oncologists: Dr. Alexander Spira, Director of the Virginia Cancer Specialists Research Institute and US Oncology Research, and Dr. Anthony Tolcher, Director of Clinical Research, Founder and CEO of NEXT Oncology. A replay of this event is available at:
  • Completed Initial Public Offering: In August 2021, Immuneering announced the closing of its upsized initial public offering of 8,625,000 shares of Class A common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $129.4 million. 
  • Three New Board of Directors Members Elected: In March 2021, Laurie Keating was elected to serve on Immuneering’s board of directors. Ms. Keating previously served as the Executive Vice President, Chief Legal Officer and Secretary of Alnylam Pharmaceuticals. 

In July 2021, Immuneering announced the appointment of Ann Berman to its board of directors. Ms. Berman was previously Vice President of Finance and Chief Financial Officer of Harvard University.

In January 2022, Diana F. Hausman, M.D. was elected to the board of directors. Dr. Hausman was previously the Chief Medical Officer of Lengo Therapeutics, a wholly-owned subsidiary of Blueprint Medicines Corporation. 

Key Development Highlights 

  • IMM-1-104 IND submission expected in Q3 2022: Immuneering expects to file the IND for IMM-1-104 in the third quarter of 2022 and enroll the first patient in its Phase 1 dose-escalating trial evaluating IMM-1-104 in patients with solid tumors with RAS mutations in the fourth quarter of this year. 
  • IMM-6-415 IND submission expected in 2023: Immuneering recently designated IMM-6-415 as a drug candidate for its MEK-io program and is currently in IND-enabling studies. IMM-6-415 is a dual-MEK inhibitor that has drug-like properties optimized for immune modulation and may enhance and/or expand clinical responses to checkpoint inhibitors in tumors that have proved historically challenging to immune modulating therapies. The company expects to file an IND application in 2023.

Fourth Quarter and Full Year 2021 Financial Highlights

  • Cash Position: Cash, cash equivalents and marketable securities as of December 31, 2021 were $150.2 million, compared with $37.1 million as of December 31, 2020. 
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2021 were $7.9 million compared with $4.9 million for the fourth quarter of 2020. Full year 2021 R&D expenses were $26.5 million compared to $15.0 million for full year 2020. The increase in R&D expenses for both periods of 2021 was primarily attributable to higher preclinical costs related to the company’s lead programs and increased personnel to support ongoing research and development activities.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2021 were $3.1 million compared with $1.1 million for the same period of 2020. Full year 2021 G&A expenses were $8.3 million compared to $3.1 million for full year 2020. The increase in G&A expenses for both periods of 2021 was primarily attributable to an increase in headcount in the company’s general and administrative functions to support the business, and costs related to preparing for the company’s initial public offering and operating as a public company.
  • Net Loss: Net loss attributable to common stockholders was $10.8 million, or $0.42 per share, for the quarter ended December 31, 2021, compared to $5.8 million, or $1.18 per share, for the quarter ended December 31, 2020. Net loss attributable to common stockholders for full year 2021 was $33.5 million, or $2.46 per share compared to $17.0 million, or $3.44 per share, for full year 2020.

2022 Financial Guidance

  • Immuneering expects full year GAAP operating expenses to be between $55.0 million and $60.0 million including estimated non-cash stock-based compensation. Based on cash, cash equivalents and marketable securities, the company expects its cash runway to extend into the third quarter of 2024. 

About Immuneering Corporation
Immuneering aims to improve patient outcomes by advancing a unique pipeline of oncology and neuroscience product candidates developed using its translational bioinformatics platform. Immuneering has more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, Immuneering’s disease-agnostic discovery platform enables the company to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry. Immuneering’s lead product candidate IMM-1-104 is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR to modulate the signaling dynamics of the MAPK pathway. Specifically, it is designed to drive deep cyclic inhibition that deprives tumor cells of the sustained proliferative signaling required for rapid growth, while providing a cadenced, moderate level of signaling sufficient to spare healthy cells. IMM-1-104 is being developed to treat advanced solid tumors in patients harboring RAS mutations, and is translationally guided by Immuneering’s proprietary, human-aligned 3D tumor modeling platform combined with patient-aligned bioinformatics. In addition to IMM-1-104, Immuneering is evaluating IMM-6-415, its MEK-io, in IND-enabling studies, and has five other oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway, as well as two discovery stage neuroscience programs.

Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements," including, without limitation, statements regarding Immuneering’s expectations regarding the sufficiency of Immuneering’s cash, cash equivalents and marketable securities, its full year GAAP operating expenses for 2022, the treatment potential of IMM-1-104 and IMM-6-415, the timing of submission of the IND and commencement of clinical trials for IMM-1-104 and IMM-6-415, and Immuneering’s ability to advance its pipeline and further diversify its portfolio and make progress towards its longstanding goal of creating better medicines for cancer patients. Forward-looking statements are based on Immuneering’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology and neuroscience drug development, including target discovery, target validation, lead compound identification, lead compound optimization, preclinical studies and clinical trials. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in Immuneering’s most recent Form 10-K filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Immuneering undertakes no duty to update such information except as required under applicable law.

Corporate Contact:
Rebecca Kusko, Ph.D.
Immuneering Corporation

Investor Contact:
Susan A. Noonan
S.A. Noonan Communications


  Three Months ended December 31 Twelve Months ended December 31
     2021    2020 2021    2020
Revenue $189,591  $665,080  $2,079,961  $2,311,535 
Cost of revenue  206,221   473,233   1,153,073   1,280,325 
Gross profit  (16,630)  191,847   926,888   1,031,210 
Operating expenses                
Research and development  7,950,488   4,890,495   26,540,959   15,003,786 
General and administrative  3,148,637   1,137,807   8,271,998   3,109,978 
Total operating expenses  11,099,125   6,028,302   34,812,957   18,113,764 
Loss from operations   (11,115,755)  (5,836,455)  (33,886,069)  (17,082,554)
Other income (expense)                
Interest income  142,885   518   169,899   42,656 
Other expense  (118,974)     (127,063)   
Loss before income taxes  (11,091,844)  (5,835,937)  (33,843,233)  (17,039,898)
Income tax benefit  307,485      307,485    
Net loss $(10,784,359) $(5,835,937) $(33,535,748) $(17,039,898)
Net loss per share attributable to common stockholders, basic and diluted  (0.42)  (1.18)  (2.46)  (3.44)
Weighted-average common shares outstanding, basic and diluted  25,977,246   4,950,129   13,612,677   4,950,129 
Other comprehensive loss:            
Unrealized losses from marketable securities  (44,258)     (49,009)   
Comprehensive Loss $(10,828,617) $(5,835,937) $(33,584,757) $(17,039,898)


     December 31, 2021    December 31, 2020
Current assets:        
Cash and cash equivalents $74,888,145  $37,090,151 
Marketable securities, current  74,311,203    
Accounts receivable  246,040   500,110 
Prepaids and other current assets  2,888,608   140,958 
Total current assets  152,333,996   37,731,219 
Marketable securities, non-current  996,560    
Property and equipment, net  807,223   64,363 
Goodwill  6,701,726    
Intangible asset  439,000    
Right-of-use assets, net  5,324,198   613,103 
Other assets  102,129   14,333 
Total assets $ 166,704,832  $ 38,423,018 
Liabilities, convertible preferred stock and stockholders' equity (deficit)        
Current liabilities:        
Accounts payable $1,394,340  $1,480,537 
Accrued expenses  3,965,447   698,992 
Lease liabilities, current  274,039   76,322 
Total current liabilities  5,633,826   2,255,851 
Long-term liabilities:        
Lease liabilities, non-current  5,090,897   544,767 
Total liabilities  10,724,723   2,800,618 
Commitments and contingencies (Note 13)        
Convertible preferred stock:        
Series B preferred stock, $0.001 par value, 0 and 6,032,183 shares authorized at December 31, 2021 and December 31, 2020, 0 and 3,619,292 shares issued and outstanding at December 31, 2021 and December 31, 2020     36,983,910 
Series A preferred stock, $0.001 par value, 0 and 2,495,933 shares authorized at December 31, 2021 and December 31, 2020, 0 and 2,495,933 shares issued and outstanding at December 31, 2021 and December 31, 2020     21,119,940 
Total convertible preferred stock     58,103,850 
Stockholders’ deficit:        
Preferred stock, $0.001 par value; 10,000,000 and 0 shares authorized at December 31, 2021 and December 31, 2020, respectively; No shares issued or outstanding      
Class A common stock, $0.001 par value, 200,000,000 and 22,026,200 shares authorized at December 31, 2021 and December 31, 2020 respectively; 26,320,199 and 4,950,129 shares issued and outstanding at December 31, 2021 and December 31, 2020  26,320   4,950 
Class B common stock, $0.001 par value, 20,000,000 and 6,032,183 shares authorized at December 31, 2021 and December 31, 2020 respectively; 0 shares issued and outstanding at December 31, 2021 and December 31, 2020      
Additional paid-in capital  215,276,186   3,251,240 
Accumulated other comprehensive loss  (49,009)   
Accumulated deficit  (59,273,388)  (25,737,640)
Total stockholders' equity (deficit)  155,980,109   (22,481,450)
Total liabilities, convertible preferred stock and stockholders' equity (deficit) $ 166,704,832  $ 38,423,018 

Print Page
Email Alerts
Email Page
RSS Feeds